The company continues to improve its pipeline.The GLP-1 market has grabbed considerable attention in the past couple of years, and there's little doubt as to which pharmaceutical companies dominate this space. Eli Lilly is currently the leader, followed closely by Novo Nordisk.However, other giants in the industry have been attempting to enter the field, and Pfizer (PFE 0.64%) is among them. Although the company has encountered some setbacks in this quest, it hasn't given up, as evidenced by a recent $5 bil ...